22.9C
Delhi
Tuesday, January 19, 2021

Bharat Biotech concludes recruitment for Covaxin’s phase 3 study

- Advertisement -

‘Covaxin likely to be available for public use by Feb’By Ashish Srivastava, (IANS) Hyderabad-based vaccine manufacturer Bharat Biotech has concluded the recruitment of volunteers for the phase III trials of its Covid vaccine, Covaxin, on Thursday after achieving the sample size it had promised to the ethics committee. The firm has achieved the targeted number of volunteers, which is 25,800 participants, in total.

The recruitment was supposed to be concluded by December 31 but was extended by a week since it was short of 4,000 volunteers that time.

Dr. Sanjay Kumar Rai, head of community medicine and principal investigator of the trial at All India Institute of All India Institute of Medical Sciences (AIIMS), Delhi told IANS that the recruitment for the phase III study is closed now.

“Around 99 per cent of the promised target was achieved by AIIMS. However, we have finished our enrollment after achieving the target in toto,” he said.

Dr. C Prabhakar Reddy, principal investigator of Covaxin’s phase III clinical trial at Nizam’s Institute of Medical Sciences, Hyderabad, said that a few sites missed their individual target by a few numbers.

READ ALSO:  India needs to fast prepare for multiple scenarios: Report

“However, the sites which over achieved their target compensated for it,” he added.

While many sites struggled to find volunteers for the phase 3 study, a few sites registered them in abundance. AIIMS Patna, one of the clinical sites for Covaxin undertook around 1,400 subjects despite its individual target set at 1,000.

IANS had earlier reported that AIIMS Delhi and several other clinical sites were facing the dearth of volunteers since people were unwilling to participate in the exercise, hoping that they would receive the vaccine anyway once it is rolled-out by the government.

The phase III study of the Covaxin, which initially spanned at 25 clinical sites across the country, inducted several more sites in the last week of December since many sites were unable to find the volunteers for the study.

READ ALSO:  Coronavirus rages in south India, experts say states ‘nearing peak’

Dr. Dhananjay Lad, co-investigator of the trial at Redkar Hospital, Goa, told IANS that the trial was extended to around 30 clinical sites.

READ ALSO:  Coronavirus rages in south India, experts say states ‘nearing peak’

“A few sites were also removed in the process because of several reasons. One of the reasons was inability to enroll a bare minimum number of participants,” he said.

The trial was started with three sites each in Uttar Pradesh (Aligarh Muslim University), West Bengal (ICMR-National Institute of Cholera and Enteric Diseases) and Tamil Nadu (Directorate of Public Health and Preventive Medicine) on November 10.

Covaxin has been given approval for restricted emergency use by India’s drug regulator. While the efficacy of the vaccine is yet to be determined, it was given a go-ahead by the Drug Controller General of India (DCGI) citing public interest.

Covaxin is indigenously developed by the Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

Aus to go ahead with Pfizer vaccine despite reported deaths

Canberra, Jan 19 (IANS) A top adviser to the Australian government has said that the country is likely to go ahead with the Pfizer...

Netaji’s birthday to be marked as ‘Parakram Diwas’ every year: Govt

New Delhi, Jan 19 (IANS) The Ministry of Culture on Tuesday said that the government has decided to celebrate the birthday of Netaji Subhas...

WHO panel highlights effective multilateralism in Covid response

Geneva, Jan 19 (IANS) A latest interim report by a WHO pandemic review panel has highlighted effective multilateralism in the preparation and response to...

Start of 2021 sees upward trend in Covid situation: WHO

Geneva, Jan 19 (IANS) Following two weeks of lower reporting towards the end of 2020, an overall upward trend of the Covid-19 pandemic has...